Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Detailed Description
-----------------
Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma. Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies. Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Official Title
-----------------
Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression

Conditions
-----------------
Melanoma; Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Blood collection for laboratory studies
* Other: Data collection from medical record


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria ≥ 18 years old at the time of informed consent Ability to provide written informed consent and HIPAA authorization Patients must have metastatic melanoma or renal cell cancer with spontaneous regression. Willingness to undergo phlebotomy for research blood samples Exclusion Criteria Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spontaneous regression<br>Patients must have metastatic melanoma or renal cell cancer with spontaneous regression. | Other: Blood collection for laboratory studies<br>* Peripheral whole blood will be collected<br>Other: Data collection from medical record<br>* Clinical data such as demographics and cancer characteristics, history and treatment will be collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of blood samples collected | samples collected from metastatic melanoma and renal cell cancer patients | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metastatic disease, spontaneous regression